Lobeline for smoking cessation

Citations of this article
Mendeley users who have this article in their library.
Get full text


Background: Lobeline is a partial nicotine agonist, which has been used in a variety of commercially available preparations to help stop smoking. Objectives: The objective of this review was to assess the effects of lobeline on long term smoking cessation. Search methods: We searched the Cochrane Tobacco Addiction Group trials register (most recent search December 2011). Selection criteria: Randomized trials comparing lobeline to placebo or an alternative therapeutic control, which reported smoking cessation with at least six months follow-up. Data collection and analysis: We extracted data in duplicate on the type of subjects, the dose and form of lobeline, the outcome measures, method of randomisation, and completeness of follow-up. Main results: We identified no trials meeting the full inclusion criteria including long term follow-up. One large trial failed to detect any effect on short-term abstinence. Authors' conclusions: There is no evidence available from long term trials that lobeline can aid smoking cessation, and the short-term evidence suggests there is no benefit




Stead, L. F., & Hughes, J. R. (2012, February 15). Lobeline for smoking cessation. Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd. https://doi.org/10.1002/14651858.CD000124.pub2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free